Flecainide acetate for the treatment of atrial and ventricular arrhythmias.

Abstract:

INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test whether the arrhythmia suppression translates into prevention of sudden death, assessed the impact of flecainide and encainide therapy in patients with frequent ventricular ectopics and reduced left ventricular function who had survived an infarction. In that population, flecainide and encainide increased mortality. Consequently, sodium channel blockers are now rarely used to prevent sudden death and are not recommended in patients with heart failure. Current European and North American guidelines recommend the use of flecainide in carefully selected patients with atrial fibrillation (AF) and no documented structural heart disease. AREAS COVERED:The aim of this review is to evaluate the available data on efficacy and safety of flecainide in all the spectrum of its indications including cardioversion of recent-onset AF, sinus rhythm maintenance in paroxysmal AF and management of ventricular tachyarrhythmias. EXPERT OPINION:In the setting of AF and in carefully selected patients without structural heart disease, flecainide has shown a good efficacy and safety for both cardioversion and sinus rhythm maintenance.

authors

Apostolakis S,Oeff M,Tebbe U,Fabritz L,Breithardt G,Kirchhof P

doi

10.1517/14656566.2013.759212

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

347-57

issue

3

eissn

1465-6566

issn

1744-7666

journal_volume

14

pub_type

杂志文章,评审
  • Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.

    abstract:INTRODUCTION:Dementia with Lewy bodies (DLB) has no approved symptomatic or disease-modifying treatments in the US and Europe, despite being the second most common cause of neurodegenerative dementia. AREAS COVERED:Herein, the authors briefly review the DLB drug development pipeline, providing a summary of the current...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1828350

    authors: Panza F,Lozupone M,Watling M,Imbimbo BP

    更新日期:2020-10-06 00:00:00

  • An evaluation of tofacitinib for the treatment of psoriatic arthritis.

    abstract::Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory condition that is associated with progressive joint destruction and reduced quality of life. Despite the common use of disease-modifying anti-rheumatic drugs (DMARDs) in PsA, their influence has been investigated in a number of studies with conflicting ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1657404

    authors: Abdulrahim H,Sharlala H,Adebajo AO

    更新日期:2019-11-01 00:00:00

  • Clinical review of Clostridium difficile infection: an update on treatment and prevention.

    abstract:INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524872

    authors: Daniels LM,Kufel WD

    更新日期:2018-11-01 00:00:00

  • Cardiac sodium channels and inherited electrophysiological disorders: an update on the pharmacotherapy.

    abstract:INTRODUCTION:Since the recognition of inherited sodium (Na(+)) channel disease, the cardiac Na(+) channel has been extensively studied. Both loss-of-function and gain-of-function mutations of the cardiac Na(+) channel are associated with cardiac arrhythmia and sudden cardiac death. Pathophysiological mechanisms that ma...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.936380

    authors: van Hoeijen DA,Blom MT,Tan HL

    更新日期:2014-09-01 00:00:00

  • Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.

    abstract::Diabetes mellitus has reached epidemic proportions in many countries and is the most common cause of end stage renal disease (ESRD). The angiotensin II receptor-1 (AT(1)) antagonists losartan and irbesartan have recently been evaluated as renoprotective agents in large clinical trials of patients with Type 2 diabetes ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.3.5.625

    authors: Doggrell SA

    更新日期:2002-05-01 00:00:00

  • Pharmacotherapeutic strategies for treating hypertension in patients with obesity.

    abstract:INTRODUCTION:Hypertension and obesity are important health challenges that independently increase cardiovascular morbidity and mortality. There is a lack of randomized controlled trials to clearly inform on preferred drug choices to be adopted in clinical practice for the treatment of obesity-related hypertension (OHT)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1458092

    authors: Carnagarin R,Matthews V,Gregory C,Schlaich MP

    更新日期:2018-05-01 00:00:00

  • Brimonidine tartrate for the treatment of glaucoma.

    abstract:INTRODUCTION:Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1544241

    authors: Oh DJ,Chen JL,Vajaranant TS,Dikopf MS

    更新日期:2019-01-01 00:00:00

  • Amyloidosis and POEMS syndrome.

    abstract:IMPORTANCE OF THE FIELD:Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. AREAS COVERED IN THI...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003769874

    authors: Chee CE,Dispenzieri A,Gertz MA

    更新日期:2010-06-01 00:00:00

  • Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

    abstract:INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1114098

    authors: Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

    更新日期:2015-01-01 00:00:00

  • Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.

    abstract:INTRODUCTION:Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a novel mechanism of action. It enh...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.706278

    authors: Orhan G,Wuttke TV,Nies AT,Schwab M,Lerche H

    更新日期:2012-08-01 00:00:00

  • Management of incomplete remission and treatment resistance in first-episode psychosis.

    abstract:BACKGROUND:Incomplete remission and treatment resistance are common even in first-episode psychosis patients. OBJECTIVE:The aim of this review was to provide an overview of the available interventions and treatment pathways for the management of incomplete remission and treatment resistance in first-episode psychosis....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2039

    authors: Lambert M,Naber D,Huber CG

    更新日期:2008-08-01 00:00:00

  • Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.

    abstract:INTRODUCTION:Treatment of complicated intra-abdominal infections (cIAIs) is becoming increasingly difficult because of the widespread emergence of multidrug-resistant organisms. AREAS COVERED:In this review, we discuss the effectiveness of several new antibiotics for the treatment of cIAIs, including new β-lactamase i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1122756

    authors: Lin SY,Huang CH,Ko WC,Chen YH,Hsueh PR

    更新日期:2016-01-01 00:00:00

  • Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.

    abstract:INTRODUCTION:Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.972364

    authors: Stirnimann G

    更新日期:2014-12-01 00:00:00

  • Vaginal ring delivery of hormone replacement therapy--a review.

    abstract::Vaginal ring delivery systems are a highly promising approach to hormone replacement therapy (HRT). The vagina is an excellent route for steroid absorption. Menopausal vaginal rings can be designed to allow very low dose local delivery of oestrogen to the vagina for the large percentage of postmenopausal women experie...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.2.201

    authors: Dezarnaulds G,Fraser IS

    更新日期:2003-02-01 00:00:00

  • Pharmacotherapy options in pulmonary alveolar proteinosis.

    abstract:INTRODUCTION:Pulmonary alveolar proteinosis (PAP) is a heterogeneous group of rare diseases characterized by the abnormal production and impaired degradation of pulmonary surfactant as a result of malfunctioning of alveolar macrophages. This is due to the downstream dysregulation of the GM-CSF pathway, which can be cau...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1757650

    authors: Antoniu SA,Rajnoveanu R,Grigore M,Antohe I

    更新日期:2020-08-01 00:00:00

  • Osteoporosis in older persons: current pharmacotherapy and future directions.

    abstract:INTRODUCTION:Osteopororic fractures are highly prevalent in older persons having catastrophic consequences in their quality of life and increasing disability and mortality in this population. The mechanisms of osteoporosis in older persons are unique in terms of cellular changes and response to osteoporosis treatment. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.822861

    authors: Duque G

    更新日期:2013-10-01 00:00:00

  • Abatacept: a novel treatment for rheumatoid arthritis.

    abstract::Rheumatoid arthritis (RA) is a chronic, autoimmune disease that has traditionally been treated with non-biologic and biologic disease-modifying antirheumatic drugs (DMARDs). Although these agents have become firmly established as effective RA treatments, some patients do not have an adequate response. The recent appro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.14.2371

    authors: Lundquist LM

    更新日期:2007-10-01 00:00:00

  • Ceftazidime for respiratory infections.

    abstract:INTRODUCTION:Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas aeruginosa. The increasing prevalence of antimicrobial resistance and the limited number of antimicrobial agents in development have necessitated a review of the current status of treatmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.721777

    authors: Choi SH,Koh Y

    更新日期:2012-10-01 00:00:00

  • Pharmacogenetics of colorectal cancer.

    abstract::Colorectal cancer is one of the most common types of cancer in both men and women. Multiple chemotherapy combinations exist; however, there is currently no strategy for individualised therapy selection prior to treatment. Genetic polymorphisms in genes involved in the metabolism, transport or targets for the commonly ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.15.2607

    authors: Marsh S

    更新日期:2005-12-01 00:00:00

  • Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review.

    abstract::Introduction: The current recommendations of chronic obstructive pulmonary disease (COPD) suggest to escalate from inhaled corticosteroid/long-acting β2-adrenoceptor agonist (ICS/LABA) treatment to triple therapy in patients experiencing persistent breathlessness, exercise limitation, or exacerbation. The addition of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1845314

    authors: Ritondo BL,Puxeddu E,Calzetta L,Cazzola M,Rogliani P

    更新日期:2020-11-11 00:00:00

  • Oxybutynin gel for the treatment of overactive bladder.

    abstract:INTRODUCTION:Overactive bladder (OAB) is a common condition that has a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. While all of the medications in this class are significantly more effective than placebo, they a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.688953

    authors: Gomelsky A,Dmochowski RR

    更新日期:2012-06-01 00:00:00

  • Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.

    abstract:BACKGROUND:This study investigated the safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin (100 mg/day) and low-dose metformin (500 or 750 mg/day). RESEARCH DESIGN AND METHODS:Fifty patients were randomly allocated to the control group (maintaining...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2017.1404576

    authors: Suzuki L,Kanazawa A,Uzawa H,Osonoi Y,Masuyama A,Azuma K,Takeno K,Takayanagi N,Sato J,Someya Y,Komiya K,Goto H,Mita T,Ikeda F,Ogihara T,Shimizu T,Ohmura C,Saito M,Osonoi T,Watada H

    更新日期:2017-12-01 00:00:00

  • Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

    abstract:OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656561003592144

    authors: Djabarouti S,Duffau P,Lazaro E,Chapouly C,Greib C,Viallard JF,Pellegrin JL,Saux MC,Breilh D

    更新日期:2010-04-01 00:00:00

  • Role of aprotinin in the management of patients during and after cardiac surgery.

    abstract::Management of patients undergoing cardiac surgery has evolved in recent years as more is understood about the physiological changes and responses that occur during and after cardiopulmonary bypass (CPB). In particular, our understanding of the mechanisms involved in haemostasis and in the inflammatory response to bypa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.7.1353

    authors: Punjabi PP,Wyse RK,Taylor KM

    更新日期:2000-12-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.879292

    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Colesevelam HCl: a non-systemic lipid-altering drug.

    abstract::Colesevelam HCl (WelChol, Sankyo Pharmaceuticals Inc.) is a bile acid sequestrant polymer, which has been shown to significantly lower low density lipoprotein cholesterol and favourably affect high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins (HMG-CoA reductase inhibitors...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.779

    authors: Bays H,Dujovne C

    更新日期:2003-05-01 00:00:00

  • Advancing treatment options for chronic idiopathic constipation.

    abstract:INTRODUCTION:Chronic constipation is a global problem affecting all ages and associated with considerable morbidity and significant financial burden for society. Though formerly defined on the basis of a single symptom, infrequent defecation; constipation is now viewed as a syndrome encompassing several complaints such...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1127356

    authors: Quigley EM,Neshatian L

    更新日期:2016-01-01 00:00:00

  • Lactic acidosis related to nucleoside therapy in HIV-infected patients.

    abstract::The incidence of nucleoside analogue-related lactic acidosis has been estimated in 0.57 - 8.5 cases/1000 person years of antiretroviral therapy. The onset of lactic acidosis is usually insidious and patients complain of nausea, vomiting, abdominal pain, fatigue and weight loss. When lactate levels are high enough, a c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.8.1321

    authors: Falcó V,Crespo M,Ribera E

    更新日期:2003-08-01 00:00:00

  • Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.

    abstract::Antiplatelet therapy is the cornerstone of treatment for patients who present with acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI). Clopidogrel, in combination with aspirin, is associated with improvement in long-term clinical outcomes in these patients and is currently the antiplatel...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.16.2893

    authors: Angiolillo DJ,Suryadevara S,Capranzano P,Bass TA

    更新日期:2008-11-01 00:00:00

  • Glatiramer acetate for the treatment of multiple sclerosis.

    abstract::Glatiramer acetate (Copaxone, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.4.875

    authors: Wolinsky JS

    更新日期:2004-04-01 00:00:00